Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 7/20 | 0.70 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.70 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.70 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.70 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.70 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8238119 | 0.94 | PRMT1 (0.69) | PRMT1PRMT3EHMT2PRMT6PRMT8 | |
| SCHEMBL362453 | 0.93 | PRMT1 (0.68) | PRMT1PRMT3EHMT2PRMT6PRMT8 | |
| SCHEMBL8229714 | 0.92 | PRMT1 (0.71) | PRMT1PRMT3EHMT2PRMT6PRMT8 | |
| Hydrochloric Acid SCHEMBL3383477 | 0.91 | PRMT1 (0.66) | PRMT1PRMT3EHMT2PRMT6PRMT8 | |
| SCHEMBL15727407 | 0.87 | PRMT1 (0.62) | PRMT1PRMT3EHMT2PRMT6PRMT8 | |
| SCHEMBL31621368 | 0.86 | PRMT1 (0.66) | PRMT1PRMT3EHMT2PRMT6PRMT8 | |
| SCHEMBL14854537 | 0.85 | PRMT1 (0.59) | PRMT1PRMT3EHMT2PRMT6PRMT8 | |
| SCHEMBL13204586 | 0.85 | PRMT1 (0.62) | PRMT1PRMT3EHMT2PRMT6PRMT8 | |
| SCHEMBL14854499 | 0.85 | PRMT1 (0.61) | PRMT1PRMT3EHMT2PRMT6PRMT8 | |
| SCHEMBL14816979 | 0.85 | PRMT1 (0.65) | PRMT1PRMT3EHMT2PRMT6PRMT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1945209-B1 | BROAD SPECTRUM ANTIBACTERIAL COMPOUNDS | US GOV AS REPRESENTED BY THE SECRETARY OF THE UNITED STATES ARMY AND THE U S ARMY MEDICAL RESEARCH (US) | 2018-05-30 | — | — | EP | disclosed |
| EP-1945209-B1 | BROAD SPECTRUM ANTIBACTERIAL COMPOUNDS | US GOV AS REPRESENTED BY THE SECRETARY OF THE UNITED STATES ARMY AND THE U S ARMY MEDICAL RESEARCH (US) | 2018-05-30 | — | — | EP | disclosed |
| WO-2013052263-A2 | ANTIFUNGAL COMPOUNDS | MICROBIOTIX, INC. (US) | 2013-04-11 | — | — | WO | disclosed |
| US-20070112048-A1 | Broad Spectrum Antibacterial Compounds | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112048-A1 | Broad Spectrum Antibacterial Compounds | MPO, CAT, LPO | PRMT1 2817/4885PRMT3 2516/4885EHMT2 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.